Drug Pricing: Where’s the Future Headed?
Summary
Avalere experts review proposed drug pricing policies from each stakeholder's perspective across the industry and the implications each might carry.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.
Consumers rate drug prices as their primary concern in healthcare. Public focus on drug pricing is also amplified by the growth in spending on prescription drugs in Medicare and Medicaid. Policymakers, state governments, and private organizations have proposed policies to address drug prices that each carries their own set of implications.
Listen to Avalere experts Elizabeth Carpenter, Rujul Desai, and Caroline Pearson discuss potential drug pricing policy changes that seek to:
- Increase transparency for pharmaceutical manufacturers and pharmacy benefit managers
- Promote competition and market-based solutions
- Medicaid reforms, including expansion funding and block grants/per-capita caps
- Limit public program spending in Medicaid, Medicare Part D and Medicare Part B
Panelists
Related Content
Services
From beginning to end, our team synergy
produces measurable results. Let's work together.
produces measurable results. Let's work together.
